| Protocol |
Title |
Status |
Contact |
| 103707 |
A Phase 1 Study of the SHP2 Inhibitor BBP 398 (formerly known as IACS 15509) in Combination with the Programmed Death Receptor 1 Blocking Antibody Nivolumab in Patients with Advanced Non Small Cell Lung Cancer with a KRAS Mutation |
OPEN TO ACCRUAL |
 |
| 103725 |
Feasibility Trial of Preoperative 5 Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma |
OPEN TO ACCRUAL |
|
| 103754 |
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma |
OPEN TO ACCRUAL |
|
| 103896 |
A Phase III Randomized Trial of Radiotherapy Optimization for Low Risk HER2 Positive Breast Cancer\" (HERO) |
OPEN TO ACCRUAL |
|
| 103848 |
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC) |
OPEN TO ACCRUAL |
|
| 103915 |
A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study) |
OPEN TO ACCRUAL |
|
| 103908 |
A Prospective Randomized Study of Ramucirumab (LY3009806;NSC749128) Plus Pembrolizumab (MK-3475;NSC776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent non-Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
| 103847 |
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer |
OPEN TO ACCRUAL |
|
| 103706 |
Risk Adapted De-Intensification of Radio Chemotherapy for Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma Based on HPV Subtype and Plasma Circulating Free HPV DNA Level and Clearance Rate. |
OPEN TO ACCRUAL |
|
| 103882 |
A Randomized Phase II Study Comparing Inotuzumab plus Chemotherapy versus Standard Chemotherapy in Older Adults with Philadelphia Chromosome Negative B Cell Acute Lymphoblastic Leukemia (ALL) |
OPEN TO ACCRUAL |
|
| 103612 |
LCCC 2047: A Phase II Trial of Induction and Maintenance Pembrolizumab and Olaparib in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) |
OPEN TO ACCRUAL |
|
| 103744 |
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer |
OPEN TO ACCRUAL |
|
| 103770 |
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR ABL positive Acute Lymphoblastic Leukemia (ALL) in Adult |
OPEN TO ACCRUAL |
|
| 103844 |
A Multi Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLAHaploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS) |
OPEN TO ACCRUAL |
|
| 103852 |
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non Muscle Invasive Bladder Cancer (BRIDGE) |
OPEN TO ACCRUAL |
|
| 103629 |
Phase II Trial of Sparing the Urethra, Pudendal Artery and Rectum During Stereotactic Ablative Body Radiotherapy (SUPR-SABR) for Favorable and Intermediate Risk Prostate Cancer |
OPEN TO ACCRUAL |
|
| 103837 |
RANDOMIZED PHASE III TRIAL OF MFOLFIRINOX +/ NIVOLUMAB VS. FOLFOX +/ NIVOLUMAB FOR FIRST LINE TREATMENT OF METASTATIC HER2 NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA |
OPEN TO ACCRUAL |
|
| 103817 |
A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator’s Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy |
OPEN TO ACCRUAL |
|
| 103873 |
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T Cell Treatment for Relapsed/Refractory Large B Cell Lymphoma or Grade IIIB Follicular Lymphoma |
OPEN TO ACCRUAL |
|
| 103799 |
A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado Trastuzumab Emtansine For Recurrent, Metastatic or Treatment Naïve, Unresectable HER-2 Positive Salivary Gland Cancer |
OPEN TO ACCRUAL |
|